Overview

A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine

Status:
Completed
Trial end date:
2019-09-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company